Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

Abstract excerpt

Intrahepatic cholangiocarcinoma (iCCA) has emerged as a promising candidate for precision medicine, especially in the case of activating FGFR2 gene fusions. In addition to fusions, a considerable fraction of iCCA patients reveals FGFR2 mutations, which might lead to uncontrolled activation of the FGFR2 pathway but are mostly of unknown functional significance. A current challenge for molecular tumor boards (MTB)...

Topics

Join the communities discussing this publication.

• Cholangiocarcinoma and Gallbladder Cancer Studies
• Fibroblast Growth Factor Research
• Pancreatic and Hepatic Oncology Research